Bio-Rad's recovery keeps slipping
- Q1 2026 sales fell 4.2% on a currency-neutral basis, with both segments down.
- Life Science fell 4.3% currency-neutral as academic research funding stayed weak, especially in the Americas.
- Clinical Diagnostics fell 4.1% currency-neutral, hurt by conflict pressure in the Middle East.
- Gross margin stayed flat at 52.3% in Q1 2026, so cost pressure has not clearly eased.
- The company also carries a large Sartorius AG equity stake, which can swing reported results apart from the core business.
The rebound is still missing
Bio-Rad has useful products and many repeat customers. Its tools help labs run research, test blood, check quality, and support clinical testing. That gives the company a real base of demand.
The problem is timing. Q1 2026 sales fell 4.2% on a currency-neutral basis, which strips out exchange-rate moves. Life Science fell 4.3% currency-neutral because academic research funding remains weak, especially in the Americas.
The larger Clinical Diagnostics segment also slipped. It fell 4.1% currency-neutral in Q1 2026, mainly tied to regional conflicts in the Middle East. Management expects that pressure to last through 2026, so the former steady segment now has its own problem.
The bull case needs a funding recovery in academic and biotech labs, steadier demand in EMEA, and better margins. The bear case is simpler: both segments are shrinking on an organic basis, and gross margin stayed flat at 52.3% in Q1 2026 with no clear recovery yet.
Recurring lab needs, cyclical budgets
Bio-Rad sells more than 12,000 products and services. The list includes reagents, lab apparatus, equipment, quality controls, and blood typing products. Many customers need the same supplies again and again, which adds a recurring piece to revenue.
Customers include universities, biotech companies, hospitals, labs, schools, governments, and health systems. That mix helps spread risk, but it also ties demand to budgets. When universities or biotech firms cut spending, Life Science can fall fast.
Clinical Diagnostics has been the larger segment and is usually steadier. In Q1 2026 it made up about 61.4% of sales, while Life Science made up about 38.6%. But diagnostics is not immune. China reimbursement pressure hurt 2025, and Middle East conflict pressure hit Q1 2026.
Bio-Rad is also global. In Q1 2026, about 39% of sales came from the United States and 61% from international markets. That reach brings growth chances, but also currency swings, trade rules, local regulations, and conflict risk.
What Bio-Rad sells
Life Science research tools
These tools help researchers separate, identify, analyze, and purify biological materials. This area can grow when academic, biotech, and biopharma funding improves, but current demand is weak.
Clinical quality controls
Quality controls help labs check that tests are working correctly. Management cited quality control products as a driver of Diagnostics growth in 2025.
Blood typing products
Blood typing products support clinical testing. They are part of the Diagnostics base and helped the segment grow in 2024 and 2025.
Reagents and consumables
Reagents are chemical or biological supplies used in tests and experiments. These can repeat as customers keep running the same workflows.
Lab apparatus and equipment
Bio-Rad sells instruments and equipment used in research and testing. These purchases can be delayed when funding is tight.
Acquired research programs
Recent acquired programs have not all worked as planned. In 2025, Bio-Rad recorded more than $200 million of in-process research and development impairments tied to Dropworks and Curiosity.
Two segments, both under pressure
Sales mix is from Q1 2026: about 38.6% Life Science and 61.4% Clinical Diagnostics. Both segments declined on a currency-neutral basis in the quarter.
What could break the thesis
Life Science funding stays weak
High impact · High oddsLife Science sales fell 4.3% currency-neutral in Q1 2026. Management tied the decline to ongoing academic research weakness, especially in the Americas. If universities, biotech firms, and government labs keep cutting or delaying purchases, the segment may not rebound soon.
Diagnostics loses its steady role
High impact · Medium oddsClinical Diagnostics was the larger segment at about 61.4% of Q1 2026 sales. It fell 4.1% currency-neutral in the quarter, mainly due to conflict pressure in the Middle East. If that pressure lasts or spreads, the company loses an important stabilizer.
Margins fail to recover
High impact · Medium oddsConsolidated gross margin was 52.3% in both Q1 2026 and Q1 2025. The lack of improvement matters because 2025 margins were hurt by higher material costs, manufacturing under-absorption, and inventory write-offs. A flat margin means the company has not yet shown clear operating repair.
M&A capital gets questioned
Medium impact · Medium oddsBio-Rad recorded more than $200 million of in-process research and development impairments in 2025 tied to Dropworks and Curiosity. That raises a fair question about deal selection, integration, and pipeline forecasting. Future acquisitions may face more investor doubt until returns are clearer.
Sartorius stake distorts results
Medium impact · High oddsBio-Rad has a large equity position in Sartorius AG. Changes in that market value can materially affect reported financial results, even when the core lab and diagnostics business has not changed much. Investors need to separate operating trends from investment gains or losses.
Global rules and currency bite
Medium impact · Medium oddsAbout 61% of Q1 2026 sales came from outside the United States. That exposes Bio-Rad to currency moves, trade limits, local tenders, and medical product rules such as FDA and foreign diagnostics regulation. Delays or added compliance costs can slow launches and pressure price.